New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer

Current Opinion in Oncology

Volumn 25, Issue 6, 2013, Pages 587-593

  Vicier, Cecile ^a   Dieci, Maria V ^a   Andre, Fabrice ^a,b  

^a Universite Paris Sud   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

breast cancer; mTOR inhibitors; resistance to rapalogs

Indexed keywords

CIXUTUMUMAB; CYCLOPHOSPHAMIDE; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RAPAMYCIN; RIDAFOROLIMUS; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG EXPOSURE; FEEDBACK SYSTEM; FOLLOW UP; GENE MUTATION; GLUCOSE METABOLISM; HORMONAL THERAPY; HUMAN; MULTIPLE MYELOMA; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; TREATMENT RESPONSE;

ANDROSTADIENES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84885434409     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000014     Document Type: Review

References (44)

1. Yu K, Toral-Barza L, Discafani C, et al. m TOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8:249-258.
2. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35.
3. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylationandregulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-1101.
4. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of m TOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296-1302.
5. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19:6680-6686.
6. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11:5319-5328.
7. Miller TW, Forbes JT, Shah C, et al. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 2009; 15:7266-7276.
8. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-529.
9. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifeninpatients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30:2718-2724.
10. Afinitor's informations. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2012/022334s016lbl.pdf http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/001038/WC50002 2814.pdf. [Accessed June 2013]
11. Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010; 28:5110-5115.
12. O'Regan R, Ozguroglu M, Andre F, et al. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzu-mab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol 2013; Presented at the 2013 ASCO Annual Meeting; June 2013; Chicago, USA; Suppl; abstr 505.
13. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-2767.
14. Gonzalez-Angulo A, Green MC, Murray JL, et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). J Clin Oncol 2011; Presented at the 2011 ASCO Annual Meeting; 3-7 June 2011; Chicago, Illinois, USA; Suppl.; abstr 1016.
15. Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120:2858-2866.
16. Janku F, Wheler JJ, Westin SN, et al. PI3K/Akt/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 777-782.
17. Alain T, Morita M, Fonseca BD, et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res 2012; 72:6468-6476.
18. Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 2013; Presented at the 2013 ASCO Annual Meeting; June 2013; Chicago, USA; Suppl.; abstr LBA509.
19. Takano A, Usui I, Haruta T, et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 2001; 21:5050-5062.
20. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-7058.
21. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-1508.
22. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166:213-223.
23. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14:1650-1656.
24. Sun XJ, Rothenberg P, Kahn CR, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991; 352:73-77.
25. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26:1932-1940.
26. Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111:379-382.
27. Shi Y, Yan H, Frost P, et al. Mammalian target of rapamycin inhibitors activate the Akt kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/ phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 4:1533-1540.
28. Oliveira JC, Souza KK, Dias MM, et al. Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts. J Cancer Res Clin Oncol 2008; 134:833-839.
29. Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007; 117:730-738.
30. Zhang H, Cicchetti G, Onda H, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 2003; 112:1223-1233.
31. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-3074.
32. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370:527-532.
33. Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007; 129:957-968.
34. Im E, von Lintig FC, Chen J, et al. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 2002; 21:6356-6365.
35. Karbowniczek M, Robertson GP, Henske EP. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J Biol Chem 2006; 281:25447-25456.
36. Choo AY, Yoon SO, Kim SG, et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008; 105:17414-17419.
37. Beretta L, Gingras AC, Svitkin YV, et al. Rapamycin blocks the phosphoryla-tion of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996; 15:658-664.
38. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelopeinthe mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011; 10:395-403.
39. Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009; 69:6232-6240.
40. Xue Q, Hopkins B, Perruzzi C, et al. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 2008; 68:9551-9557.
41. Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res 2011; 71:1573-1583.
42. Naing A, Kurzrock R, Burger A, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 2011; 17:6052-6060.
43. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011; 17:871-879.
44. Tabernero J, Cervantes A, Gordon MS. A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies. Cancer Res 2012; 72 (Suppl. 1); Presented at the AACR Annual Meeting 2012; Chicago, USA.